Information Provided By:
Fly News Breaks for October 21, 2015
AGN, TEVA
Oct 21, 2015 | 08:22 EDT
Cowen said the financial and strategic rationale for Teva's (TEVA) acquisition of Allergan's (AGN) generics division remains solid, as it will have a profound impact on its value creation with its potential synergies. The firm also sees Teva well positioned for future branded acquisitions and reiterated its Outperform rating and $100 price target on Teva shares.
News For TEVA;AGN From the Last 2 Days
There are no results for your query TEVA;AGN